NRSNW (NeuroSense Therapeutics) Research & Development: $6.23 Mil (TTM As of Dec. 2025)


NRSNW NeuroSense Therapeutics Ltd NRSNW
29 GF Score
Price $0.21
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Research & Development?

NeuroSense Therapeutics NRSNW 29 Research & Development is $6.23 Mil as of Dec. 2025. GuruFocus rates NRSNW with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. NeuroSense Therapeutics's Research & Development for the six months ended in Dec. 2025 was $3.72 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $6.23 Mil.

NeuroSense Therapeutics  (NAS:NRSNW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NeuroSense Therapeutics Research & Development Related Terms

NeuroSense Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Research & Development Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 3.08 5.59 7.27 5.70 6.23

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.46 3.73 1.97 2.50 3.72
NRSNW
29GF Score
NeuroSense Therapeutics Ltd NRSNW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $6.23 Mil mean?
NeuroSense Therapeutics (NRSNW) has a Research & Development of $6.23 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Research & Development too high?
NeuroSense Therapeutics' current Research & Development is $6.23 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Research & Development compare to SNTI and LSTA?
NeuroSense Therapeutics' Research & Development of $6.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Research & Development is $6.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSNW) has a current Research & Development of $6.23 Mil. The current Research & Development is $6.23 Mil. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSNW), the current Research & Development is $6.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges NRSN:USAH1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSNW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price